NCT05436444View on ClinicalTrials.gov

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions
Influenza Infection
Interventions
BIOLOGICAL

A/Mallard/Ohio-99/MM4/1989 H10N7

The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05436444 - Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model | Biotech Hunter | Biotech Hunter